Jatenzo Pharmacogenomics: How Your Genes Shape Oral Testosterone Response

How Jatenzo Works: The Lymphatic Absorption Pathway

Jatenzo delivers testosterone undecanoate (TU) as a self-emulsifying oral capsule taken twice daily with food. Unlike older oral androgens such as methyltestosterone, TU exploits the intestinal lymphatic system to reach systemic circulation. This pathway sidesteps first-pass hepatic metabolism, which historically destroyed oral testosterone before it could reach target tissues [1].

Lymphatic Uptake and the Role of Dietary Fat

The undecanoate ester attached to testosterone is a long-chain fatty acid (C11). When ingested with a meal containing at least 15 to 30 g of fat, TU is incorporated into chylomicrons within intestinal enterocytes. These chylomicrons drain into mesenteric lymph nodes and enter systemic blood via the thoracic duct, delivering testosterone directly to the venous system [2]. Patients who take Jatenzo in a fasted state absorb roughly 50% less drug. Genetic variation in intestinal lipid transporters, including polymorphisms in the MTTP gene (microsomal triglyceride transfer protein), may partly explain the 20 to 30% inter-individual variability in TU bioavailability reported in pharmacokinetic studies [1].

Ester Cleavage and Active Hormone Release

Once TU reaches the bloodstream, esterases rapidly cleave the undecanoate side chain, releasing free testosterone. This testosterone then follows normal metabolic pathways: conversion to dihydrotestosterone (DHT) via 5-alpha reductase, conversion to estradiol via aromatase (CYP19A1), and hepatic clearance through phase I oxidation and phase II conjugation [3]. Each of these steps is subject to genetic variation, which is why two men on the same Jatenzo dose can have measurably different serum testosterone, DHT, and estradiol concentrations.

CYP3A4: The Gatekeeper of Testosterone Oxidation

CYP3A4 is the dominant cytochrome P450 enzyme responsible for the 6-beta-hydroxylation of testosterone, its primary oxidative clearance route. The CYP3A4 gene is highly polymorphic, with over 40 known allelic variants cataloged by the Pharmacogene Variation Consortium [4].

Clinically Relevant CYP3A4 Variants

The CYP3A422 allele (rs35599367, intron 6 SNP) reduces hepatic CYP3A4 expression by approximately 30 to 40%. Carriers of CYP3A422 metabolize testosterone more slowly, which can lead to higher steady-state testosterone and DHT concentrations on a fixed Jatenzo dose [4]. The allele frequency is roughly 5 to 8% in European populations and <2% in African and East Asian populations [5].

The CYP3A41B allele (rs2740574, promoter variant) has been associated with modestly increased enzyme activity in some studies, though results are inconsistent. Men carrying CYP3A41B may clear testosterone faster and require doses at the upper end of the Jatenzo range to maintain eugonadal levels [5].

Drug-Drug Interactions Compounding Genetic Effects

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can mimic the pharmacokinetic effect of a slow-metabolizer genotype, raising testosterone exposure substantially. The Jatenzo prescribing information warns against concomitant use with strong CYP3A4 inhibitors for this reason [1]. A man who is both a CYP3A4*22 carrier and taking a moderate CYP3A4 inhibitor faces a compounded reduction in clearance. This "double-hit" scenario is not addressed in current labeling but represents a practical pharmacogenomic concern that warrants closer monitoring of serum testosterone and hematocrit.

UGT2B17: The Enzyme That Clears 90% of Testosterone

Uridine diphosphate-glucuronosyltransferase 2B17 (UGT2B17) catalyzes the glucuronidation of testosterone and its metabolites, accounting for the majority of phase II elimination. A common copy number variation (CNV) results in complete gene deletion (del/del genotype), which dramatically reduces testosterone glucuronidation capacity [6].

Population Frequencies of UGT2B17 Deletion

The del/del genotype frequency varies strikingly across ancestry groups. In European-descent populations, approximately 9 to 12% of men carry the homozygous deletion. In East Asian populations, that figure rises to 60 to 67% [6]. This is one of the largest ancestry-linked pharmacogenomic differences known in endocrinology.

Clinical Consequences for Jatenzo Dosing

Men with the UGT2B17 del/del genotype clear testosterone more slowly and tend to have higher baseline urinary testosterone glucuronide ratios. On exogenous testosterone, these individuals may achieve target serum concentrations at lower doses. A pharmacokinetic modeling study by Jakobsson et al. Demonstrated that UGT2B17 deletion status significantly predicted testosterone area-under-the-curve after exogenous administration [6]. For Jatenzo specifically, this means that East Asian patients and the ~10% of European-descent patients carrying del/del may be over-treated at standard starting doses if clinicians do not monitor early and adjust accordingly.

No commercial pharmacogenomic panel currently bundles CYP3A4, UGT2B17, SHBG, and AR CAG repeat testing into a single "testosterone optimization" report. Building a HealthRX-specific decision framework that maps genotype combinations to Jatenzo starting-dose tiers and monitoring intervals would represent genuine clinical utility not available elsewhere.

SHBG Gene Polymorphisms and Free Testosterone Availability

Sex hormone-binding globulin (SHBG) binds approximately 40 to 65% of circulating testosterone with high affinity, rendering it biologically inactive at the receptor level. Only free testosterone (1 to 3% of total) and albumin-bound testosterone exert androgenic effects at target tissues [7].

The rs6258 Variant

A missense variant in the SHBG gene (rs6258, Asp327Asn) reduces SHBG binding affinity for testosterone. Men carrying this variant have 10 to 15% higher calculated free testosterone at any given total testosterone level [7]. In the context of Jatenzo therapy, a carrier achieving a total testosterone of 500 ng/dL may have the free testosterone equivalent of a non-carrier at 575 ng/dL. This has real implications for dose titration: total testosterone alone does not capture the pharmacodynamic picture.

SHBG Promoter Polymorphisms

The SHBG (TAAAA)n promoter repeat polymorphism also influences SHBG production. Longer repeat alleles (more than 8 repeats) correlate with lower SHBG transcription and lower circulating SHBG concentrations [8]. Men with long-repeat alleles have higher free testosterone fractions at baseline and on therapy. When titrating Jatenzo, checking both total testosterone and calculated free testosterone (using the Vermeulen equation or equilibrium dialysis) gives a more pharmacogenomically informed assessment than total testosterone alone.

Androgen Receptor CAG Repeats: End-Organ Sensitivity

The androgen receptor (AR) gene on the X chromosome contains a polymorphic CAG trinucleotide repeat in exon 1. This repeat encodes a polyglutamine tract in the N-terminal transactivation domain of the receptor. Shorter CAG repeat lengths (10 to 16 repeats) produce a receptor with stronger transcriptional activity, while longer repeats (25 to 35) reduce receptor sensitivity [9].

What This Means for Jatenzo Response

Two men with identical serum testosterone levels can experience different clinical outcomes based on their AR CAG repeat length. A man with 15 CAG repeats may report excellent libido, energy, and body composition improvements on Jatenzo 237 mg twice daily. A man with 28 CAG repeats at the same dose and the same serum level may report minimal symptomatic improvement [9].

Ethnic Distribution of CAG Repeats

Average CAG repeat length varies by ancestry. African-descent men tend to have shorter repeats (mean ~18 to 20), European-descent men cluster around 21 to 22, and East Asian-descent men average 22 to 23 [10]. These population-level differences do not predict individual response, but they add another layer to the pharmacogenomic variability that shapes Jatenzo outcomes across diverse patient populations.

The Endocrine Society's 2018 clinical practice guideline for testosterone therapy acknowledges that AR sensitivity modifies treatment response but stops short of recommending routine CAG repeat testing [11]. The practical barrier is interpretive: there is no validated CAG repeat cutoff that triggers a specific dose change.

SRD5A2 Polymorphisms and DHT Conversion

The SRD5A2 gene encodes steroid 5-alpha reductase type 2, the enzyme that converts testosterone to DHT in prostate, skin, and hair follicle tissues. DHT is roughly three to ten times more potent than testosterone at the androgen receptor [3].

The V89L Variant

The V89L polymorphism (rs523349) in SRD5A2 reduces enzyme activity by approximately 30%. Men homozygous for the leucine allele (LL genotype) convert less testosterone to DHT [12]. On Jatenzo, these patients may have a higher testosterone-to-DHT ratio compared with men carrying the wild-type valine allele. The clinical significance cuts both ways: lower DHT conversion could mean less androgenic stimulation of the prostate (potentially favorable) but also reduced DHT-dependent benefits such as libido and sexual function.

The A49T Variant

The A49T substitution (rs9282858) increases 5-alpha reductase activity roughly fivefold in vitro. This rare variant (allele frequency <2% in most populations) has been associated with higher DHT levels and, in some epidemiologic studies, modestly increased prostate cancer risk [12]. Men carrying A49T who are started on Jatenzo may produce disproportionately high DHT levels relative to their total testosterone, a pattern that warrants monitoring via serum DHT measurement during titration.

Aromatase (CYP19A1) Variation and Estradiol Levels

CYP19A1 encodes aromatase, which converts testosterone to estradiol. A tetranucleotide (TTTA)n repeat polymorphism in intron 4 influences aromatase expression in adipose tissue [13]. Men with longer repeat alleles tend to have higher aromatase activity, producing more estradiol per unit of testosterone.

Implications During Jatenzo Therapy

Elevated estradiol on testosterone replacement can cause gynecomastia, water retention, and mood disturbance. In the Swerdloff et al. Key trial of Jatenzo, 87% of patients achieved eugonadal testosterone at 3 months, but a subset experienced DHT and estradiol elevations above the reference range [1]. Genetically high aromatizers may account for a disproportionate share of estradiol-related adverse effects. Measuring estradiol at 4 to 6 weeks after Jatenzo initiation and at each dose titration identifies these patients before symptoms develop.

The CYP19A1 rs10046 SNP (3'-UTR variant) has also been linked to circulating estradiol levels in genome-wide association studies, with the T allele associated with higher estradiol in men [13]. While no prescribing algorithm currently integrates this SNP, it represents a plausible future target for pharmacogenomic-guided testosterone therapy.

Putting It Together: A Pharmacogenomic-Informed Approach to Jatenzo

No single gene determines Jatenzo response. The clinical picture emerges from the combined effects of absorption variability (MTTP, dietary fat intake), oxidative metabolism (CYP3A4), conjugative clearance (UGT2B17), binding protein dynamics (SHBG), receptor sensitivity (AR CAG repeats), DHT conversion (SRD5A2), and estradiol generation (CYP19A1) [14].

Practical Monitoring Recommendations

The Endocrine Society guideline recommends checking serum testosterone 3 to 5 hours after the morning dose during Jatenzo titration, with hematocrit monitoring at 3 to 6 months and then annually [11]. Adding free testosterone (calculated or by equilibrium dialysis), DHT, and estradiol to the initial monitoring panel costs relatively little and captures pharmacogenomic variability that total testosterone alone misses.

Who Benefits Most from Pharmacogenomic Awareness

Patients who fail to reach eugonadal levels despite maximum-dose Jatenzo (396 mg twice daily) or who develop disproportionate DHT or estradiol elevations on low doses are the clearest candidates for pharmacogenomic consideration. CYP3A4 and UGT2B17 genotyping is available through commercial panels such as those offered by OneOme RightMed and Tempus xG, though testosterone-specific clinical decision support is limited in current platforms [14].

The 13% of patients in the Swerdloff trial who did not achieve target testosterone at 3 months likely included a mix of poor absorbers, rapid metabolizers, and men with high SHBG binding [1]. Pharmacogenomics does not yet offer a complete explanation, but it narrows the differential from "idiopathic non-response" to a testable set of biological hypotheses.

Current serum testosterone measured at steady state remains the gold standard for Jatenzo dose titration, with a target Cavg of 300 to 1,050 ng/dL per the FDA-approved label [1].